The Checkpoint Therapeutics share is experiencing a dramatic course jump after the Indian pharmaceutical company Sun Pharma announced the takeover of the biotech company. The takeover volume amounts to a three -digit million amount.
• Strategic takeover: Sun Pharma extends oncology portfolio
• Strengthening the global market position
• Checkpoint therapeutics share with an enormous course jump
The Indian pharmaceutical company Sun Pharmaceutical, SUN Pharma for short, has announced the takeover of Checkpoint Therapeutics, as can be seen from a press release from the weekend. With this step, Sun Pharma strengthens its portfolio in the field of oncology and biotechnology. Checkpoint therapeutics specializes in innovative cancer therapies and develops, among other things, immune checkpoint inhibitors.
Strategic takeover
The takeover of Checkpoint Therapeutics is part of Sun Pharma’s long -term growth strategy. The company plans to expand its market presence in the field of cancer therapies and to benefit from the promising developments in the field of immunoncology, according to Reuters. Checkpoint Therapeutics brings promising preservative candidates for active ingredients, including Cosibelimab, a potential immune checkpoint inhibitor that is located in the late clinical development phase. “The combination of Unloxcyt, an anti-PD-L1 treatment for advanced Kutanes squamous cell carcinoma, with the global presence of Sun Pharma, means that patients with CSCC could soon have access to an important new treatment option. SUN PHARMA, quoted in the press release. “I am proud of the commitment and passion of our team at Checkpoint, which made it possible for us to develop the first and only anti-PD-L1 treatment for patients with advanced CSCC approved by the FDA, and we look forward to taking this transaction with Sun Pharma to make Unloxcyt CSCC patients accessible that a differentiated Immunotherapy treatment option need, “said James Oliviero, President and Chief Executive Officer from Checkpoint Therapeutics. “Sun Pharma is in harmony with checkpoints commitment to improve the life of skin cancer patients, and I am convinced that this transaction will maximize the value for our shareholders and that faster access to Unloxcyt in the United States, Europe and other markets will enable worldwide.”
Strengthening the global market position
With the takeover, Sun Pharma not only secures new therapy approaches, but also better access to the US and international pharmaceutical market. Oncology is one of the most growth segments of the Pharmaceutical industryand with Checkpoint Therapeutics, Sun Pharma can further deepen his commitment in this area.
Deal in three -digit millions
The deal volume should amount to up to $ 355 million, because Sun Pharma $ 4.10 as an advance payment for every checkpoint therapeutics share, according to the corresponding press release from Checkpoint Therapeutics. This advance payment corresponds to a surcharge of about 66 percent on the recent final course of Checkpoint Therapeutics on March 7 at $ 2.47. In addition, the shareholders should receive a conditional right of value of up to $ 0.70 per share when a milestone is reached.
Currently, Checkpoint Therapeutics noted that the takeover is still subject to approval by the shareholders of Checkpoint Therapeutics and other usual final conditions.
Investors are already celebrating the upcoming takeover. The Checkpoint therapeutics share on Monday in pre-exchanged Nasdaq trading at times jumps by 67.21 percent high to $ 4.13. The Sun Pharma papers in India gained slightly 0.08 percent to 1,611.15 Indian rupees.
Editor finance.net
Selected leverage products on Checkpoint therapeutics
With knock-outs, speculative investors can participate disproportionately in price movements. Simply choose the desired lever and we will show you suitable open-end products on Checkpoint therapeutics
The lever must be between 2 and 20
Advertising